Effects of lovastatin and pravastatin on ubiquinone and 4- hydroxynonenal tissue levels in the hypercholesterolemic hamster

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 2, 2000, Pages 87-104

  Rousseau, Guy ^a   Véronneau, Marc ^a   DesRosiers, Christine ^a   Varin, France ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

4 hydroxynonenal; Hamster; Lovastatin; Myocardium; Pravastatin; Ubiquinone

Indexed keywords

4 HYDROXYNONENAL; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; UBIQUINONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; HAMSTER; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID ANALYSIS; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033041761     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88486-6     Document Type: Editorial

References (59)

1. Rousseau G, Des Rosiers C, Varin F. A comparison of the effects of lovastatin and pravastatin on tissue ubiquinone levels in the rat. Curr Ther Res. 1998;59:666-679.
2. Komai T, Tsujita Y. Hepatocyte selectivity of HMG-CoA reductase inhibitors. Drug News Perspect. 1994;7:279-288.
3. Tsujita Y, Ikeda T, Serizawa N, et al. Pravastatin sodium: New clinical aspects and recent progress. Annu Rep Sankyo Res Lab. 1997;49:1-61.
4. Vliet van AK, van Thiel GCF, Holger Huisman R, et al. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim Biophys Acta. 1995;1254:105-111.
5. Löw P, Andersson M, Edlund C, Dallner G. Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta. 1992;1165:102-109.
6. Pinieux de G, Chariot P, Ammi-Saïd M, et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42:333-337.
7. Mortensen SA, Leth A, Agner E, Rohde M. Dose related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18 (Suppl):S137-S144.
8. Human JA, Ubbink JB, Jerling JJ, et al. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia. Clin Chim Acta. 1997; 263:67-77.
9. Thompson PD, Zmuda JM, Domalik LJ, et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46:1206-1210.
10. Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol. 1997; 145:99-110.
11. Masters BA, Palmoski MJ, Flint OP, et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 1995;131:163-174.
12. Vliet van AK, Nègre-Aminou P, van Thiel GCF, et al. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle. Biochem Pharmacol. 1996;52:1387-1392.
13. Fujioka T, Nara F, Tsujita Y, et al. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta. 1995;1254:7-12.
14. Tsujita Y, Kuroda M, Shimada Y, et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta. 1986;877:50-60.
15. Yoshino G, Matsushita M, Iwai M, et al. Effect of pravastatin on newly-secreted very low density lipoprotein composition in rats. Horm Metab Res. 1991;23:193-195.
16. Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-1659.
17. Spady DK, Meddings JB, Dietschy JM. Kinetic constants for receptor-dependent and receptor-independent low density lipoprotein transport in the tissues of the rat and hamster. J Clin Invest. 1986;77:1474-1481.
18. Spady DK, Dietschy JM. Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster. J Clin Invest. 1988; 81:300-309.
19. Spady DK, Turley SD, Dietschy JM. Rates of low density lipoprotein uptake and cholesterol synthesis are regulated independently in the liver. J Lipid Res. 1985;26:465-472.
20. Hayashi K, Noshiro M, Kurushima H, et al. Effect of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on hepatic cholesterol 7α-hydroxylase, acyl-coenzyme A: Cholesterol acyltransferase, and bile lipid secretion in the hamster with intact enterohepatic circulation. Atherosclerosis. 1994;111:183-189.
21. Ma PTS, Gil G, Südhof TC, et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA. 1986;83:8370-8374.
22. Yamamoto A, Itoh S, Hoshi K, Ichihara K. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis. Res Commun Mol Pathol Pharmacol. 1994;86:325-334.
23. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195-204.
24. Thomas SR, Neuzil J, Stocker R. Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis? Mol Asp Med. 1997;18(Suppl):S85-S103.
25. Nohl H, Gille L, Staniek K. Endogenous and exogenous regulation of redox-properties of coenzyme Q. Mol Asp Med. 1997;18(Suppl):S33-S40.
26. Niki E. Mechanisms and dynamics of antioxidant action of ubiquinol. Mol Asp Med. 1997;18(Suppl):S63-S70.
27. Beyer RE. The relative essentiality of the antioxidative function of coenzyme Q - the interactive role of DT-diaphorase. Mol Asp Med. 1994;15(Suppl):S117-S129.
28. Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. Biochem Biophys Res Commun. 1990; 169:851-857.
29. Ernster L, Forsmark P, Nordenbrand K. The mode of action of lipid-soluble antioxidants in biological membranes: Relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles. Biofactors. 1992;3:241-248.
30. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
31. Blasig IE, Grune T, Schonheit K, et al. 4-Hydroxynonenal, a novel indicator of lipid peroxidation for reperfusion injury of the myocardium. Am J Physiol. 1995;269(1 Pt 2): H14-H22.
32. Hanaki Y, Sugiyama S, Ozawa T, Ohno M. Coenzyme Q10 and coronary artery disease. Clin Invest. 1993;71(Suppl):S112-S115.
33. Pogue DH, Moravec CS, Roppelt C, et al. Effect of lovastatin on cholesterol content of cardiac and red blood cell membranes in normal and cardiomyopathic hamsters. J Pharmacol Exp Ther. 1995;273:863-869.
34. Lang JK, Packer L. Quantitative determination of vitamin E and oxidized and reduced coenzyme Q by high-performance liquid chromatography with in-line ultraviolet and electrochemical detection. J Chromatogr. 1987;385:109-117.
35. Harris N, Neufeld EJ, Newburger JW, et al. Analytical performance and clinical utility of a direct LDL-cholesterol assay in a hyperlipidemic pediatric population. Clin Chem. 1996;42:1182-1188.
36. Belcher JD, McNamara JR, Grinstead GF, et al. Measurement of low-density lipoprotein cholesterol concentration. In: Rifai N, Warnick GR, eds. Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. Washington, DC: AACC Press; 1994:107-123.
37. Jialal I, Hirany SV, Devaraj S, Sherwood TA. Comparison of an immunoprecipitation method for direct measurement of LDL-cholesterol with β-quantification (ultracentrifugation). Am J Clin Pathol. 1995;104:76-81.
38. Rousseau G, Varin F. Determination of ubiquinone-9 and -10 levels in rat tissues and blood by high performance liquid chromatography with ultraviolet detection. J Chromatogr Sci. 1998;36:247-252.
39. Des Rosiers C, Rivest M-J, Boily M-J, et al. Gas chromatographic-mass spectrometric assay of tissue malondialdehyde, 4-hydroxynonenal, and other aldehydes after their reduction to stable alcohols. Anal Biochem. 1993;208:161-170.
40. Uchida K, Stadtman ER. Selective cleavage of thioether linkage in proteins modified with 4-hydroxynonenal. Proc Natl Acad Sci USA. 1992;89:5611-5615.
41. Plancke MO, Olivier Ph, Clavey V, et al. Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamster. Influence of fenofibrate. Methods Find Exp Clin Pharmacol. 1988;10:575-579.
42. Shimomura I, Bashmakov Y, Shimano H, et al. Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver. Proc Natl Acad Sci USA. 1997;94:12,354-12,359.
43. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32:403-425.
44. Pedren̄o J, Sánchez JL, Zambón D, Ros E. In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: Evidence of lack of stimulatory effect of pravastatin. Coron Artery Dis. 1994;512:971-977.
45. Glinn MA, Lee CP, Ernster L. Pro- and anti-oxidant activities of the mitochondrial respiratory chain: Factors influencing NAD(P)H-induced lipid peroxidation. Biochim Biophys Acta. 1997;1318:246-254.
46. Schnurr K, Hellwing M, Seidermann B, et al. Oxygenation of biomembranes by mammalian lipoxygenases: The role of ubiquinone. Free Radic Biol Med. 1996;20:11-21.
47. Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and in vivo studies. Atherosclerosis. 1992;93:105-113.
48. Salonen R, Nyyssönen K, Porkkala-Sarataho E, Salonen JT. The Kuopio atherosclerosis prevention study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995;76(Suppl):34C-39C.
49. Singh RB, Singh NK, Rastogi SS, et al. Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc Drugs Ther. 1997;11:575-580.
50. Leonhardt W, Kurktschiev T, Meissner D, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol. 1997;53:65-69.
51. Aviram M, Hussein O, Rosenblat M, et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: Antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol. 1998;31:39-45.
52. Nozaki S, Vega GL, Haddox RJ, et al. Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis. 1990;84:101-110.
53. Graaf de J, Hak-Lemmers HLM, Hectors MPC, et al. Enhanced susceptibility to in vitro oxidation of the dense LDL subfraction in healthy subjects. Arterioscler Thromb. 1991; 11:298-306.
54. Pré J. Radicaux libres et peroxydation lipidique: I. Aspects biologiques généraux. Sem Hop. 1992;68:1430-1437.
55. Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and α-tocopherol during lovastatin treatment. FEBS Lett. 1997;410:254-258.
56. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998;138:271-280.
57. Scholz RW, Minicucci LA, Reddy CC. Effects of vitamin E and selenium on antioxidant defense in rat heart. Biochem Mol Biol Int. 1997;42:997-1006.
58. Wakabayashi H, Yamato S, Nakajima M, Shimada K. Simultaneous determination of oxidized and reduced coenzyme Q and α-tocopherol in biological samples by high performance liquid chromatography with platinum catalyst reduction and electrochemical detection. Biol Pharm Bull. 1994;17:997-1002.
59. Noack H, Kube U, Augustin W. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria. Free Radic Res. 1994;20:375-386.